Zeru Tian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zeru Tian has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Han Xiao
Department of Chemistry, Rice University, Houston, USA
5 shared publications - Ling Wu
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, USA
5 shared publications - Xiang H.-F. Zhang
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
5 shared publications - Anna Reva
Icahn School of Medicine, Mount Sinai, New York, New York
4 shared publications - Bora Lim
Department of Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA
4 shared publications - Bree M. Lege
Department of Molecular and Human Genetics, Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
4 shared publications
Latest Publications
- Open Access
- 23 August 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (59) , e74762
Esterified Cholesterol Conjugates Enable LNP‐Mediated mRNA Delivery to the Blood–Brain Barrier Following Intravenous Administration
The blood–brain barrier (BBB) plays a critical role in maintaining central nervous system homeostasis by regulating molecular and cellular exchange between the brain and peripheral circulation. While most delivery strategies focus on crossing the BBB, targeting brain endothelial cells directly may offer a complementary and more controlled alternative for therapeutic intervention. This study presents a ligand‐free lipid nanoparticle (LNP) platform that enables efficient mRNA delivery to the brain endothelium via systemic administration. A modular synthesis strategy was used to generate a chemically diverse library of cholesterol‐based lipids. Screening of 486 LNPs identified an optimized four‐component formulation consisting of C6O2B2 (novel cholesterol‐based lipid), DODAP, DSPC, and DMG‐PEG, which achieves high transfection efficiency in brain endothelial cells without the incorporation of free cholesterol or disruption of BBB integrity and function, such as those utilized in focused ultrasound (FUS) techniques. This BBB‐targeting LNP platform avoids neuronal and glial transfection, thereby offering a noninvasive, and scalable approach for cerebrovascular gene delivery. The work establishes a new class of cholesterol‐based lipids and provides a foundation for next‐generation RNA therapeutics targeting BBB‐associated diseases.
- 23 August 2026
- Published by Wiley in Advanced Materials
- Vol. 38 (59) , e74762
Open AccessEsterified Cholesterol Conjugates Enable LNP‐Mediated mRNA Delivery to the Blood–Brain Barrier Following Intravenous Administration
The blood–brain barrier (BBB) plays a critical role in maintaining central nervous system homeostasis by regulating molecular and cellular exchange between the brain and peripheral circulation. While most delivery strategies focus on crossing the BBB, targeting brain endothelial cells directly may offer a complementary and more controlled alternative for therapeutic intervention. This study presents a ligand‐free lipid nanoparticle (LNP) platform that enables efficient mRNA delivery to the brain endothelium via systemic administration. A modular synthesis strategy was used to generate a chemically diverse library of cholesterol‐based lipids. Screening of 486 LNPs identified an optimized four‐component formulation consisting of C6O2B2 (novel cholesterol‐based lipid), DODAP, DSPC, and DMG‐PEG, which achieves high transfection efficiency in brain endothelial cells without the incorporation of free cholesterol or disruption of BBB integrity and function, such as those utilized in focused ultrasound (FUS) techniques. This BBB‐targeting LNP platform avoids neuronal and glial transfection, thereby offering a noninvasive, and scalable approach for cerebrovascular gene delivery. The work establishes a new class of cholesterol‐based lipids and provides a foundation for next‐generation RNA therapeutics targeting BBB‐associated diseases.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2− Breast Cancer
Supplementary Figure 1 Shows the distribution of ERBB2 mutations among metastatic cancer patients, survival outcomes according to metastatic sites (bone vs visceral), and detailed CTC counts from HR+/Her2- MBC patients. Supplementary Figure 2 Shows the therapeutic effect of Tras-ALN on metastasis spread from bone metastasis models of HR+ breast cancer via uCT, live and ex vivo bioluminescence profiling of metastatic organs. Supplementary Figure 3 shows the increased expression of ERBB2 in MSC 3D coculture and anti-ER treatment conditions. Supplementary Figure 4 shows the immune-independent effect of Tras-ALN in blocking metastasis progression. Supplementary Figure 5 shows that direct cell-cell interaction is not required for MSC-induced Her2 expression based on 3D transwell culture conditions. Supplementary 1 of Figure 6 shows genetic modulations of Her2 (ERBB2) in MCF7 and ZR75-1 breast cancer models. Supplementary 2 of Figure 6 shows that genetic alteration of Her2 impacts multiorgan metastasis seeding in HR+ breast cancer models. Supplementary 1 of Figure 7 shows that miRNAs with Her2 targeting potential are associated with overall survival in breast cancer. Supplementary 2 of Figure 7 shows that miR-133a/b abrogates brain metastasis seeding from bone-derived ZR75-1 cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2− Breast Cancer
Supplementary Figure 1 Shows the distribution of ERBB2 mutations among metastatic cancer patients, survival outcomes according to metastatic sites (bone vs visceral), and detailed CTC counts from HR+/Her2- MBC patients. Supplementary Figure 2 Shows the therapeutic effect of Tras-ALN on metastasis spread from bone metastasis models of HR+ breast cancer via uCT, live and ex vivo bioluminescence profiling of metastatic organs. Supplementary Figure 3 shows the increased expression of ERBB2 in MSC 3D coculture and anti-ER treatment conditions. Supplementary Figure 4 shows the immune-independent effect of Tras-ALN in blocking metastasis progression. Supplementary Figure 5 shows that direct cell-cell interaction is not required for MSC-induced Her2 expression based on 3D transwell culture conditions. Supplementary 1 of Figure 6 shows genetic modulations of Her2 (ERBB2) in MCF7 and ZR75-1 breast cancer models. Supplementary 2 of Figure 6 shows that genetic alteration of Her2 impacts multiorgan metastasis seeding in HR+ breast cancer models. Supplementary 1 of Figure 7 shows that miRNAs with Her2 targeting potential are associated with overall survival in breast cancer. Supplementary 2 of Figure 7 shows that miR-133a/b abrogates brain metastasis seeding from bone-derived ZR75-1 cells.
- 30 August 2025
- Published by Elsevier in Biomaterials
- Vol. 326, 123671
Investigating the functional contributions of phospholipids in selective organ targeting lipid nanoparticles
- 30 August 2025
- Published by Elsevier in Biomaterials
- Vol. 326, 123671
Investigating the functional contributions of phospholipids in selective organ targeting lipid nanoparticles
- Open Access
- 2 April 2025
- Published by American Association for Cancer Research (AACR)
Data from Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2− Breast Cancer
Bone metastases can disseminate to secondary sites and promote breast cancer progression, creating additional clinical challenges. The mechanisms contributing to secondary metastasis are barely understood. Here, we evaluate the prediction power of HER2-expressing (HER2E) circulating tumor cells (CTC) after analyzing over 13,000 CTCs from a cohort of 137 patients with metastatic breast cancer with initial HR+/HER2− status and use preclinical models of bone metastasis (BM) to validate the role of HER2E CTCs in multiorgan metastases. Although HER2 expression was higher in patients with BM, experimental analyses revealed that HER2E CTCs derived from bone lesions were more dependent on HER2 activity and more susceptible to anti-HER2 therapy. Targeting the bone-mediated HER2 induction reduces CTC detection and abrogates secondary metastasis from the bone. Overall, we elucidate that HER2E CTCs can serve as a noninvasive biomarker for BM formation with high therapeutic benefit for patients with HR+ metastatic breast cancer.Significance:Given the urgent need for alternative strategies to block metastasis progression, we demonstrate that blocking HER2-mediated secondary metastasis improves clinical outcome and establish HER2 as a biomarker for bone metastasis in patients with initial HR+/HER2− breast cancer, which represents ∼70% of all cases.
- 2 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2− Breast Cancer
Bone metastases can disseminate to secondary sites and promote breast cancer progression, creating additional clinical challenges. The mechanisms contributing to secondary metastasis are barely understood. Here, we evaluate the prediction power of HER2-expressing (HER2E) circulating tumor cells (CTC) after analyzing over 13,000 CTCs from a cohort of 137 patients with metastatic breast cancer with initial HR+/HER2− status and use preclinical models of bone metastasis (BM) to validate the role of HER2E CTCs in multiorgan metastases. Although HER2 expression was higher in patients with BM, experimental analyses revealed that HER2E CTCs derived from bone lesions were more dependent on HER2 activity and more susceptible to anti-HER2 therapy. Targeting the bone-mediated HER2 induction reduces CTC detection and abrogates secondary metastasis from the bone. Overall, we elucidate that HER2E CTCs can serve as a noninvasive biomarker for BM formation with high therapeutic benefit for patients with HR+ metastatic breast cancer.Significance:Given the urgent need for alternative strategies to block metastasis progression, we demonstrate that blocking HER2-mediated secondary metastasis improves clinical outcome and establish HER2 as a biomarker for bone metastasis in patients with initial HR+/HER2− breast cancer, which represents ∼70% of all cases.
- Open Access
- 2 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2− Breast Cancer
Supplementary Figure 1 Shows the distribution of ERBB2 mutations among metastatic cancer patients, survival outcomes according to metastatic sites (bone vs visceral), and detailed CTC counts from HR+/Her2- MBC patients. Supplementary Figure 2 Shows the therapeutic effect of Tras-ALN on metastasis spread from bone metastasis models of HR+ breast cancer via uCT, live and ex vivo bioluminescence profiling of metastatic organs. Supplementary Figure 3 shows the increased expression of ERBB2 in MSC 3D coculture and anti-ER treatment conditions. Supplementary Figure 4 shows the immune-independent effect of Tras-ALN in blocking metastasis progression. Supplementary Figure 5 shows that direct cell-cell interaction is not required for MSC-induced Her2 expression based on 3D transwell culture conditions. Supplementary 1 of Figure 6 shows genetic modulations of Her2 (ERBB2) in MCF7 and ZR75-1 breast cancer models. Supplementary 2 of Figure 6 shows that genetic alteration of Her2 impacts multiorgan metastasis seeding in HR+ breast cancer models. Supplementary 1 of Figure 7 shows that miRNAs with Her2 targeting potential are associated with overall survival in breast cancer. Supplementary 2 of Figure 7 shows that miR-133a/b abrogates brain metastasis seeding from bone-derived ZR75-1 cells.
- 2 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2− Breast Cancer
Supplementary Figure 1 Shows the distribution of ERBB2 mutations among metastatic cancer patients, survival outcomes according to metastatic sites (bone vs visceral), and detailed CTC counts from HR+/Her2- MBC patients. Supplementary Figure 2 Shows the therapeutic effect of Tras-ALN on metastasis spread from bone metastasis models of HR+ breast cancer via uCT, live and ex vivo bioluminescence profiling of metastatic organs. Supplementary Figure 3 shows the increased expression of ERBB2 in MSC 3D coculture and anti-ER treatment conditions. Supplementary Figure 4 shows the immune-independent effect of Tras-ALN in blocking metastasis progression. Supplementary Figure 5 shows that direct cell-cell interaction is not required for MSC-induced Her2 expression based on 3D transwell culture conditions. Supplementary 1 of Figure 6 shows genetic modulations of Her2 (ERBB2) in MCF7 and ZR75-1 breast cancer models. Supplementary 2 of Figure 6 shows that genetic alteration of Her2 impacts multiorgan metastasis seeding in HR+ breast cancer models. Supplementary 1 of Figure 7 shows that miRNAs with Her2 targeting potential are associated with overall survival in breast cancer. Supplementary 2 of Figure 7 shows that miR-133a/b abrogates brain metastasis seeding from bone-derived ZR75-1 cells.
- 21 January 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (4) , 818-837
Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2− Breast Cancer
Bone metastases can disseminate to secondary sites and promote breast cancer progression, creating additional clinical challenges. The mechanisms contributing to secondary metastasis are barely understood. Here, we evaluate the prediction power of HER2-expressing (HER2E) circulating tumor cells (CTC) after analyzing over 13,000 CTCs from a cohort of 137 patients with metastatic breast cancer with initial HR+/HER2− status and use preclinical models of bone metastasis (BM) to validate the role of HER2E CTCs in multiorgan metastases. Although HER2 expression was higher in patients with BM, experimental analyses revealed that HER2E CTCs derived from bone lesions were more dependent on HER2 activity and more susceptible to anti-HER2 therapy. Targeting the bone-mediated HER2 induction reduces CTC detection and abrogates secondary metastasis from the bone. Overall, we elucidate that HER2E CTCs can serve as a noninvasive biomarker for BM formation with high therapeutic benefit for patients with HR+ metastatic breast cancer. Significance: Given the urgent need for alternative strategies to block metastasis progression, we demonstrate that blocking HER2-mediated secondary metastasis improves clinical outcome and establish HER2 as a biomarker for bone metastasis in patients with initial HR+/HER2− breast cancer, which represents ∼70% of all cases.
- 21 January 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (4) , 818-837
Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2− Breast Cancer
Bone metastases can disseminate to secondary sites and promote breast cancer progression, creating additional clinical challenges. The mechanisms contributing to secondary metastasis are barely understood. Here, we evaluate the prediction power of HER2-expressing (HER2E) circulating tumor cells (CTC) after analyzing over 13,000 CTCs from a cohort of 137 patients with metastatic breast cancer with initial HR+/HER2− status and use preclinical models of bone metastasis (BM) to validate the role of HER2E CTCs in multiorgan metastases. Although HER2 expression was higher in patients with BM, experimental analyses revealed that HER2E CTCs derived from bone lesions were more dependent on HER2 activity and more susceptible to anti-HER2 therapy. Targeting the bone-mediated HER2 induction reduces CTC detection and abrogates secondary metastasis from the bone. Overall, we elucidate that HER2E CTCs can serve as a noninvasive biomarker for BM formation with high therapeutic benefit for patients with HR+ metastatic breast cancer. Significance: Given the urgent need for alternative strategies to block metastasis progression, we demonstrate that blocking HER2-mediated secondary metastasis improves clinical outcome and establish HER2 as a biomarker for bone metastasis in patients with initial HR+/HER2− breast cancer, which represents ∼70% of all cases.
- Open Access
- 25 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (26) , eabf2051
Harnessing the power of antibodies to fight bone metastasis
Precision modification of antibodies with bone-targeting moieties unleashes their potential for the treatment of bone metastases.
- 25 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (26) , eabf2051
Open AccessHarnessing the power of antibodies to fight bone metastasis
Precision modification of antibodies with bone-targeting moieties unleashes their potential for the treatment of bone metastases.
- 1 March 2021
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 28 (9) , 1775-1795
Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Background: Currently, cancer continues being a dramatically increasing and serious threat to public health. Although many anti-tumor agents have been developed in recent years, the survival rate of patients is not satisfactory. The poor prognosis of cancer patients is closely related to the occurrence of drug resistance. Therefore, it is urgent to develop new strategies for cancer treatment. Multi-target therapies aim to have additive or synergistic effects and reduce the potential for the development of resistance by integrating different pharmacophores into a single drug molecule. Given the fact that majority of diseases are multifactorial in nature, multi-target therapies are being exploited with increasing intensity, which has brought improved outcomes in disease models and obtained several compounds that have entered clinical trials. Thus, it is potential to utilize this strategy for the treatment of BRD4 related cancers. This review focuses on the recent research advances of dual-target inhibitors based on BRD4 in the aspect of anti-tumor. Methods: We have searched the recent literatures about BRD4 inhibitors from the online resources and databases, such as pubmed, elsevier and google scholar. Results: In the recent years, many efforts have been taken to develop dual-target inhibitors based on BRD4 as anti-cancer agents, such as HDAC/BRD4 dual inhibitors, PLK1/BRD4 dual inhibitors and PI3K/BRD4 dual inhibitors and so on. Most compounds display good anti-tumor activities. Conclusion: Developing new anti-cancer agents with new scaffolds and high efficiency is a big challenge for researchers. Dual-target inhibitors based on BRD4 are a class of important bioactive compounds. Making structural modifications on the active dual-target inhibitors according to the corresponding structure-activity relationships is of benefit to obtain more potent anti-cancer leads or clinical drugs. This review will be useful for further development of new dual-target inhibitors based on BRD4 as anti-cancer agents.
- 1 March 2021
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 28 (9) , 1775-1795
Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Background: Currently, cancer continues being a dramatically increasing and serious threat to public health. Although many anti-tumor agents have been developed in recent years, the survival rate of patients is not satisfactory. The poor prognosis of cancer patients is closely related to the occurrence of drug resistance. Therefore, it is urgent to develop new strategies for cancer treatment. Multi-target therapies aim to have additive or synergistic effects and reduce the potential for the development of resistance by integrating different pharmacophores into a single drug molecule. Given the fact that majority of diseases are multifactorial in nature, multi-target therapies are being exploited with increasing intensity, which has brought improved outcomes in disease models and obtained several compounds that have entered clinical trials. Thus, it is potential to utilize this strategy for the treatment of BRD4 related cancers. This review focuses on the recent research advances of dual-target inhibitors based on BRD4 in the aspect of anti-tumor. Methods: We have searched the recent literatures about BRD4 inhibitors from the online resources and databases, such as pubmed, elsevier and google scholar. Results: In the recent years, many efforts have been taken to develop dual-target inhibitors based on BRD4 as anti-cancer agents, such as HDAC/BRD4 dual inhibitors, PLK1/BRD4 dual inhibitors and PI3K/BRD4 dual inhibitors and so on. Most compounds display good anti-tumor activities. Conclusion: Developing new anti-cancer agents with new scaffolds and high efficiency is a big challenge for researchers. Dual-target inhibitors based on BRD4 are a class of important bioactive compounds. Making structural modifications on the active dual-target inhibitors according to the corresponding structure-activity relationships is of benefit to obtain more potent anti-cancer leads or clinical drugs. This review will be useful for further development of new dual-target inhibitors based on BRD4 as anti-cancer agents.
- Open Access
- 1 January 2021
- Published by Elsevier in SSRN Electronic Journal
Synthesis of Precision Antibody Conjugates Using Proximity-Induced Chemistry
To produce homogeneous antibody conjugates, antibody engineering or chemical/enzymatic treatments are required, processes that often affect antibody folding and stability, as well as yield and cost. Here, we describe a simple proximity-induced antibody conjugation method (pClick) that enables the synthesis of homogeneous antibody conjugates from native antibodies without requiring additional antibody engineering or post-synthesis treatment. A proximity-activated crosslinker is introduced into a chemically synthesized affinity peptide modified with a bioorthogonal handle. Upon binding to a specific antibody site, the affinity peptide covalently attaches to the antibody via spontaneous crosslinking, yielding an antibody molecule ready for bioorthogonal conjugation with payloads. We have prepared well-defined antibody-drug conjugates and bispecific small molecule-antibody conjugates, exhibiting excellent in vitro cytotoxic activity against cancer cells and superb antitumor activity in mouse xenograft models. This technology does not require antibody engineering or additional UV/chemical/enzymatic treatments, therefore providing a general, convenient strategy for developing novel antibody conjugates.
- 1 January 2021
- Published by Elsevier in SSRN Electronic Journal
Open AccessSynthesis of Precision Antibody Conjugates Using Proximity-Induced Chemistry
To produce homogeneous antibody conjugates, antibody engineering or chemical/enzymatic treatments are required, processes that often affect antibody folding and stability, as well as yield and cost. Here, we describe a simple proximity-induced antibody conjugation method (pClick) that enables the synthesis of homogeneous antibody conjugates from native antibodies without requiring additional antibody engineering or post-synthesis treatment. A proximity-activated crosslinker is introduced into a chemically synthesized affinity peptide modified with a bioorthogonal handle. Upon binding to a specific antibody site, the affinity peptide covalently attaches to the antibody via spontaneous crosslinking, yielding an antibody molecule ready for bioorthogonal conjugation with payloads. We have prepared well-defined antibody-drug conjugates and bispecific small molecule-antibody conjugates, exhibiting excellent in vitro cytotoxic activity against cancer cells and superb antitumor activity in mouse xenograft models. This technology does not require antibody engineering or additional UV/chemical/enzymatic treatments, therefore providing a general, convenient strategy for developing novel antibody conjugates.